Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies

Cellular and Molecular Immunology

Volumn 8, Issue 1, 2011, Pages 75-82

  Jiang, Yanfang ^a   Li, Wanyu ^a   Yu, Lei ^a   Liu, Jingjing ^a   Xin, Guijie ^a   Yan, Hongqing ^a   Sun, Pinghui ^a   Zhang, Hong ^a   Xu, Damo ^b   Niu, Junqi ^a  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ADV; cytokine; ETV; HBV; Treg

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CYTOKINES; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOMODULATION; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE;

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS B VIRUS;

EID: 79952461990     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.37     Document Type: Article

References (27)

1. WHO. Hepatitis B. Geneva: WHO, 2008.
2. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439-1449. (Pubitemid 43827198)
3. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006; 3: 97-106.
4. Billerbeck E, Bottler T, Thimme R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13: 4858-4864. (Pubitemid 47496751)
5. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71: 2192-2201. (Pubitemid 27078599)
6. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turningon newborn T cellswith dendritic cells. Science 1996; 271: 1723-1726. (Pubitemid 26102819)
7. Chisari FV. CytotoxicTcells andviral hepatitis. J Clin Invest 1997; 99: 1472-1477.
8. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatoryTcellsand enhancestheantiviral immune response in chronic hepatitis B. Virology 2007; 361: 141-148. (Pubitemid 46551232)
9. Chang TT, Gish RG, de MR, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354: 1001-1010. (Pubitemid 43357804)
10. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al. Entecavirversus lamivudinefor patients with HBeAg-negativechronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
11. + T-cell reactivity. Antimicrob Agents Chemother 2008; 52: 312-320.
12. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108. (Pubitemid 351975535)
13. Duramad P, McMahon CW, Hubbard A, Eskenazi B, Holland NT. Flow cytometric detection of intracellular TH1/TH2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2004; 13: 1452-8. (Pubitemid 39202311)
14. + Tregcells. J Exp Med 2006;203:1701-1711. (Pubitemid 44036276)
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241. (Pubitemid 33096596)
16. Buster EH, Janssen HL. Antiviral treatment for chronic hepatitis B virus infection\immune modulation or viral suppression? Neth J Med 2006; 64: 175-185. (Pubitemid 43970918)
17. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444. (Pubitemid 350029745)
18. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after48weeksof adefovirdipivoxil monotherapy. Hepatology 2006; 43: 1385-1391. (Pubitemid 43980117)
19. Leung N, Peng CY, Sollano J, Lesmana L, Yuen MF, Jeffers L, et al. Entecavir (ETV) results in higher HBV DNA reductionversusadefovir (ADV) in antiviral-naive HBeAḡ adults with high HBV DNA: week 96 results (E.A.R.L.Y. Study) [abstract]. J Hepatol 2008; 48(Suppl 2)S373-S374.
20. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747. (Pubitemid 43939189)
21. + T-cell proliferationandTh1 cytokinesecretion inpatientswithchronichepatitis B. World J Gastroenterol 2007; 13: 5440-5445.
22. McClary H, Koch R,Chisari FV, Guidotti LG. Relativesensitivityof hepatitis Bvirusand other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264. (Pubitemid 30091480)
23. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-upof HBeAg-positive patientstreated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427. (Pubitemid 26157437)
24. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral responsetohepatitis Bvirusthatdestabilizesnucleocapsidsandreducesnuclearviral DNA. J Virol 2007; 81: 7351-7362. (Pubitemid 47047824)
25. Guidotti LG, Guilhot S, Chisari FV. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and-independent pathways. J Virol 1994; 68: 1265-1270. (Pubitemid 24065687)
26. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
27. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positivechronic hepatitis B. Hepatology 2008; 48: 750-758.